


Fexapotide TFA

Cat. No.:	HY-P3501A
Molecular Formula:	$C_{90}H_{163}N_{27}O_{25}S \cdot xC_2HF_3O_2$
Sequence:	Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu
Sequence Shortening:	IDQQVLSRIKLEIKRCL
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research^{[1][2][3]}.

REFERENCES

- [1]. Shore N, et al. Efficacy and safety of fexapotide trifluate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. *Ther Adv Urol*. 2019 Jan 14;11:1756287218820807.
- [2]. Shore N, et al. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. *Ther Adv Chronic Dis*. 2011 Nov;2(6):377-83.
- [3]. Shore N, et al. Fexapotide trifluate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. *World J Urol*. 2018 May;36(5):801-809.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA